The AMLo board is fortunate to have appointed David Macdonald as Non-Executive Director with effect from 1 June 2021. AMLo’s ambitions include launching AMBLor® for ‘rule-out’ of low risk patients with a melanoma diagnosis in the USA, the world’s biggest melanoma market. AMLo is due to submit AMBLor® to the US Federal Drug Administration (FDA) in 2021 and Mr. Macdonald will help advise the board on all strategic and commercial activities for the USA.
He brings significant, valuable experience from roles as Division President and COO at Quest Diagnostics, CEO at Agendia and most recently as CEO of First Light Diagnostics, among others. David has a deep understanding of the steps required to commercialise medical devices in the USA and significantly strengthens the executive team’s capabilities. He has raised over $160m privately and led companies through successful exits.
CEO of AMLo Biosciences, Dr Marie Labus said:
“David’s appointment marks a significant step forward in achieving AMLo’s milestones and we are very keen to work with him to refine and implement our US entry strategy for AMBLor.”
David responded by saying:
“I am really excited to be working with this Newcastle-based spin-out, as the USA clearly represents a great market opportunity for AMBLor.”
David Macdonald has an extensive, successful track record in M&A integration, fund raising, strategic planning and business plan execution in complex life science companies, large and small, public, and private. He has been an invited speaker at a variety of industry events and has served on several industry Advisory Boards and Boards of Directors.
David holds a BSBA degree in Management and Finance from Northeastern University and an MBA from Babson College with a focus on Marketing and Entrepreneurship.